New EU Filings
Executive Summary
Asciminib, Novartis's drug for patients with chronic myeloid leukemia, is among the latest new medicines that have been submitted for pan-EU approval.
You may also be interested in...
Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU
The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.